Drugs / IMB071703
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06292858 | Feb 2023 → Apr 2025 | cancer | Beijng Immunoah Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMB071703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06292858 ↗ |